Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02992522
Title Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Beth Christian

follicular lymphoma

B-cell lymphoma


Lenalidomide + Obinutuzumab + Venetoclax

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.